Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs in Active & Progressive MS
NCT02166021Phase 2Completed
- Start
- Jan 2015
- Primary completion
- Jun 2018
- Modality
- Stem Cell Therapies, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MSC-NG01 in multiple sclerosis (MS) (3 arms). Primary endpoints: Safety Assessment at 12 months and Neurological efficacy at 12 months. Started Jan 2015; status: completed.
02
Drugs
MSC-NG01
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02166021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166021.